Format

Send to

Choose Destination
Curr Opin Clin Nutr Metab Care. 2015 Jan;18(1):78-82. doi: 10.1097/MCO.0000000000000122.

Arginine deprivation in cancer therapy.

Author information

1
aSylvester Comprehensive Cancer Center, University of Miami, Miami, Florida bDepartment of Translational Molecular Pathology, The University of Texas MD, Anderson Cancer Center, Houston, Texas cSylvester Comprehensive Cancer Center, University of Miami, VA Medical Center, Miami, Florida, USA.

Abstract

PURPOSE OF REVIEW:

There has been an increased and renewed interest in metabolic therapy for cancer, particularly Arg deprivation. The purpose of this review is to highlight recent studies that focus on Arg-dependent malignancies with Arginine (Arg)-degrading enzymes, including arginase and Arg deiminase.

RECENT FINDINGS:

New developments in this area include understanding of the role of most significantly downregulated gene regulating amino acid metabolism, argininosuccinate synthetase and its expression and therapeutic relevance in different tumors. Recent studies have also shed light on the mechanism of tumor cell death with Arg deprivation, with arginase and pegylated Arg deiminase. Particularly important is understanding the mechanism of resistance that cancers develop after such drug exposure. Finally, recent clinical trials have been performed or are ongoing to use Arg deprivation as treatment for advanced malignancies.

SUMMARY:

Arg deprivation is a promising approach for the treatment of various malignancies.

PMID:
25474015
DOI:
10.1097/MCO.0000000000000122
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center